NL
Therapeutic Areas
TopAlliance Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LOQTORZI (Toripalimab) | Nasopharyngeal Carcinoma (and other undisclosed oncology indications) | Approved |
| Undisclosed ADC Programs | Oncology | Not Disclosed |
Leadership Team at TopAlliance Biosciences
SY
Sheng Yao, Ph.D.
Chief Executive Officer and Executive Director
PK
Patricia Keegan, M.D.
Chief Medical Officer
KL
Kevin Li, Ph.D.
Vice President of Regulatory Affairs
MH
Monica Hughes
Vice President of Project and Portfolio Management